These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 27382031)

  • 61. REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer.
    Nakajima H; Kotani D; Bando H; Kato T; Oki E; Shinozaki E; Sunakawa Y; Yamazaki K; Yuki S; Nakamura Y; Yamanaka T; Yoshino T; Ohta T; Taniguchi H; Kagawa Y
    BMC Cancer; 2021 Jun; 21(1):674. PubMed ID: 34098908
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer.
    Sclafani F; Kim TY; Cunningham D; Kim TW; Tabernero J; Schmoll HJ; Roh JK; Kim SY; Park YS; Guren TK; Hawkes E; Clarke SJ; Ferry D; Frödin JE; Ayers M; Nebozhyn M; Peckitt C; Loboda A; Mauro DJ; Watkins DJ
    J Natl Cancer Inst; 2015 Dec; 107(12):djv258. PubMed ID: 26405092
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients.
    Elez E; Pericay C; Valladares-Ayerbes M; Bando I; Safont MJ; Gallego J; Grávalos C; Arrivi A; Carrato A; Conde V; Ortiz MJ; López C; Alonso B; Ruiz de Mena I; Díaz-Rubio E; Tabernero J; Aranda E
    Br J Cancer; 2019 Aug; 121(5):378-383. PubMed ID: 31363167
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effect of BRAF V600E mutation on tumor response of anti-EGFR monoclonal antibodies for first-line metastatic colorectal cancer treatment: a meta-analysis of randomized studies.
    Cui D; Cao D; Yang Y; Qiu M; Huang Y; Yi C
    Mol Biol Rep; 2014 Mar; 41(3):1291-8. PubMed ID: 24390240
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Mucinous Histology Is Associated with Resistance to Anti-EGFR Therapy in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer.
    Wang C; Sandhu J; Fakih M
    Oncologist; 2022 Mar; 27(2):104-109. PubMed ID: 35641204
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The impact of primary tumor localization on survival and treatment outcomes in patients with metastatic colorectal cancer-a multicenter study.
    Sahin S; Karatas F
    J BUON; 2019; 24(2):479-487. PubMed ID: 31127994
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab.
    Scartozzi M; Mandolesi A; Giampieri R; Bittoni A; Pierantoni C; Zaniboni A; Galizia E; Giustini L; Silva RR; Bisonni R; Berardi R; Biscotti T; Biagetti S; Bearzi I; Cascinu S
    Oncologist; 2011; 16(1):53-60. PubMed ID: 21212430
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Watanabe J; Muro K; Shitara K; Yamazaki K; Shiozawa M; Ohori H; Takashima A; Yokota M; Makiyama A; Akazawa N; Ojima H; Yuasa Y; Miwa K; Yasui H; Oki E; Sato T; Naitoh T; Komatsu Y; Kato T; Hihara M; Soeda J; Misumi T; Yamamoto K; Akagi K; Ochiai A; Uetake H; Tsuchihara K; Yoshino T
    JAMA; 2023 Apr; 329(15):1271-1282. PubMed ID: 37071094
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cetuximab in the treatment of patients with colorectal cancer.
    Garrett CR; Eng C
    Expert Opin Biol Ther; 2011 Jul; 11(7):937-49. PubMed ID: 21557708
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Clinical Impact of PI3K/BRAF Mutations in RAS Wild Metastatic Colorectal Cancer: Meta-analysis Results.
    Mohamed A; Twardy B; AbdAllah N; Akhras A; Ismail H; Zordok M; Schrapp K; Attumi T; Tesfaye A; El-Rayes B
    J Gastrointest Cancer; 2019 Jun; 50(2):269-275. PubMed ID: 29388061
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy?
    Paez D; Paré L; Espinosa I; Salazar J; del Rio E; Barnadas A; Marcuello E; Baiget M
    Cancer Sci; 2010 Sep; 101(9):2048-53. PubMed ID: 20550522
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer.
    Sforza V; Martinelli E; Ciardiello F; Gambardella V; Napolitano S; Martini G; Della Corte C; Cardone C; Ferrara ML; Reginelli A; Liguori G; Belli G; Troiani T
    World J Gastroenterol; 2016 Jul; 22(28):6345-61. PubMed ID: 27605871
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer.
    Kim TW; Elme A; Park JO; Udrea AA; Kim SY; Ahn JB; Valencia RV; Krishnan S; Manojlovic N; Guan X; Lofton-Day C; Jung AS; Vrdoljak E
    Clin Colorectal Cancer; 2018 Sep; 17(3):206-214. PubMed ID: 29703606
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy.
    Lin JK; Lin AJ; Lin CC; Lan YT; Yang SH; Li AF; Chang SC
    J Surg Oncol; 2011 Nov; 104(6):661-6. PubMed ID: 21671463
    [TBL] [Abstract][Full Text] [Related]  

  • 76. FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study.
    Personeni N; Rimassa L; Verusio C; Barni S; Rubino L; Bozzarelli S; Villa E; Carnaghi C; Tronconi MC; Gerardi C; Galli F; Floriani I; Destro A; Raschioni C; Labianca R; Santoro A
    Clin Colorectal Cancer; 2015 Sep; 14(3):162-9. PubMed ID: 25861836
    [TBL] [Abstract][Full Text] [Related]  

  • 77.
    van Brummelen EMJ; de Boer A; Beijnen JH; Schellens JHM
    Oncologist; 2017 Jul; 22(7):864-872. PubMed ID: 28576857
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials.
    Peeters M; Price T; Taieb J; Geissler M; Rivera F; Canon JL; Pentheroudakis G; Koukakis R; Burdon P; Siena S
    Br J Cancer; 2018 Aug; 119(3):303-312. PubMed ID: 30013091
    [TBL] [Abstract][Full Text] [Related]  

  • 80. CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer.
    Zhang X; Shimodaira H; Soeda H; Komine K; Takahashi H; Ouchi K; Inoue M; Takahashi M; Takahashi S; Ishioka C
    Int J Clin Oncol; 2016 Dec; 21(6):1091-1101. PubMed ID: 27435270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.